Global Dermatomyositis Drug Sales Market Report 2017

REPORT ID 3597

Global Dermatomyositis Drug Sales Market Report 2017

Publish Date

14-Dec-17

Pages

116

Format

Electronic (PDF)

Full report description

In this report, the global Dermatomyositis Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Dermatomyositis Drug for these regions, from 2012 to 2022 (forecast), covering
    United States
    China
    Europe
    Japan
    Southeast Asia
    India

Global Dermatomyositis Drug market competition by top manufacturers/players, with Dermatomyositis Drug sales volume, Price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    MedImmune LLC
    Neovacs SA
    Novartis AG
    Octapharma AG
    Pfizer Inc
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    Hope Pharmaceuticals Inc
    Idera Pharmaceuticals Inc
    KPI Therapeutics Inc
    Marathon Pharmaceuticals LLC
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Abatacept
    Baricitinib
    Dalazatide
    Immune Globulin
    IMO-8400
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Clinic
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of contents

Table of Contents

Global Dermatomyositis Drug Sales Market Report 2017
1 Dermatomyositis Drug Market Overview
    1.1 Product Overview and Scope of Dermatomyositis Drug
    1.2 Classification of Dermatomyositis Drug by Product Category
        1.2.1 Global Dermatomyositis Drug Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 Global Dermatomyositis Drug Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Abatacept
        1.2.4 Baricitinib
        1.2.5 Dalazatide
        1.2.6 Immune Globulin
        1.2.7 IMO-8400
        1.2.8 Others
    1.3 Global Dermatomyositis Drug Market by Application/End Users
        1.3.1 Global Dermatomyositis Drug Sales (Volume) and Market Share Comparison by Application (2012-2022)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Global Dermatomyositis Drug Market by Region
        1.4.1 Global Dermatomyositis Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 United States Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.3 China Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.4 Europe Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.5 Japan Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.6 Southeast Asia Dermatomyositis Drug Status and Prospect (2012-2022)
        1.4.7 India Dermatomyositis Drug Status and Prospect (2012-2022)
    1.5 Global Market Size (Value and Volume) of Dermatomyositis Drug (2012-2022)
        1.5.1 Global Dermatomyositis Drug Sales and Growth Rate (2012-2022)
        1.5.2 Global Dermatomyositis Drug Revenue and Growth Rate (2012-2022)

2 Global Dermatomyositis Drug Competition by Players/Suppliers, Type and Application
     2.1 Global Dermatomyositis Drug Market Competition by Players/Suppliers
        2.1.1 Global Dermatomyositis Drug Sales and Market Share of Key Players/Suppliers (2012-2017)
        2.1.2 Global Dermatomyositis Drug Revenue and Share by Players/Suppliers (2012-2017)
    2.2 Global Dermatomyositis Drug (Volume and Value) by Type
        2.2.1 Global Dermatomyositis Drug Sales and Market Share by Type (2012-2017)
        2.2.2 Global Dermatomyositis Drug Revenue and Market Share by Type (2012-2017)
    2.3 Global Dermatomyositis Drug (Volume and Value) by Region
        2.3.1 Global Dermatomyositis Drug Sales and Market Share by Region (2012-2017)
        2.3.2 Global Dermatomyositis Drug Revenue and Market Share by Region (2012-2017)
    2.4 Global Dermatomyositis Drug (Volume) by Application

3 United States Dermatomyositis Drug (Volume, Value and Sales Price)
    3.1 United States Dermatomyositis Drug Sales and Value (2012-2017)
        3.1.1 United States Dermatomyositis Drug Sales and Growth Rate (2012-2017)
        3.1.2 United States Dermatomyositis Drug Revenue and Growth Rate (2012-2017)
        3.1.3 United States Dermatomyositis Drug Sales Price Trend (2012-2017)
    3.2 United States Dermatomyositis Drug Sales Volume and Market Share by Players
    3.3 United States Dermatomyositis Drug Sales Volume and Market Share by Type
    3.4 United States Dermatomyositis Drug Sales Volume and Market Share by Application

4 China Dermatomyositis Drug (Volume, Value and Sales Price)
    4.1 China Dermatomyositis Drug Sales and Value (2012-2017)
        4.1.1 China Dermatomyositis Drug Sales and Growth Rate (2012-2017)
        4.1.2 China Dermatomyositis Drug Revenue and Growth Rate (2012-2017)
        4.1.3 China Dermatomyositis Drug Sales Price Trend (2012-2017)
    4.2 China Dermatomyositis Drug Sales Volume and Market Share by Players
    4.3 China Dermatomyositis Drug Sales Volume and Market Share by Type
    4.4 China Dermatomyositis Drug Sales Volume and Market Share by Application

5 Europe Dermatomyositis Drug (Volume, Value and Sales Price)
    5.1 Europe Dermatomyositis Drug Sales and Value (2012-2017)
        5.1.1 Europe Dermatomyositis Drug Sales and Growth Rate (2012-2017)
        5.1.2 Europe Dermatomyositis Drug Revenue and Growth Rate (2012-2017)
        5.1.3 Europe Dermatomyositis Drug Sales Price Trend (2012-2017)
    5.2 Europe Dermatomyositis Drug Sales Volume and Market Share by Players
    5.3 Europe Dermatomyositis Drug Sales Volume and Market Share by Type
    5.4 Europe Dermatomyositis Drug Sales Volume and Market Share by Application

6 Japan Dermatomyositis Drug (Volume, Value and Sales Price)
    6.1 Japan Dermatomyositis Drug Sales and Value (2012-2017)
        6.1.1 Japan Dermatomyositis Drug Sales and Growth Rate (2012-2017)
        6.1.2 Japan Dermatomyositis Drug Revenue and Growth Rate (2012-2017)
        6.1.3 Japan Dermatomyositis Drug Sales Price Trend (2012-2017)
    6.2 Japan Dermatomyositis Drug Sales Volume and Market Share by Players
    6.3 Japan Dermatomyositis Drug Sales Volume and Market Share by Type
    6.4 Japan Dermatomyositis Drug Sales Volume and Market Share by Application

7 Southeast Asia Dermatomyositis Drug (Volume, Value and Sales Price)
    7.1 Southeast Asia Dermatomyositis Drug Sales and Value (2012-2017)
        7.1.1 Southeast Asia Dermatomyositis Drug Sales and Growth Rate (2012-2017)
        7.1.2 Southeast Asia Dermatomyositis Drug Revenue and Growth Rate (2012-2017)
        7.1.3 Southeast Asia Dermatomyositis Drug Sales Price Trend (2012-2017)
    7.2 Southeast Asia Dermatomyositis Drug Sales Volume and Market Share by Players
    7.3 Southeast Asia Dermatomyositis Drug Sales Volume and Market Share by Type
    7.4 Southeast Asia Dermatomyositis Drug Sales Volume and Market Share by Application

8 India Dermatomyositis Drug (Volume, Value and Sales Price)
    8.1 India Dermatomyositis Drug Sales and Value (2012-2017)
        8.1.1 India Dermatomyositis Drug Sales and Growth Rate (2012-2017)
        8.1.2 India Dermatomyositis Drug Revenue and Growth Rate (2012-2017)
        8.1.3 India Dermatomyositis Drug Sales Price Trend (2012-2017)
    8.2 India Dermatomyositis Drug Sales Volume and Market Share by Players
    8.3 India Dermatomyositis Drug Sales Volume and Market Share by Type
    8.4 India Dermatomyositis Drug Sales Volume and Market Share by Application

9 Global Dermatomyositis Drug Players/Suppliers Profiles and Sales Data
    9.1 MedImmune LLC
        9.1.1 Company Basic Information, Manufacturing Base and Competitors
        9.1.2 Dermatomyositis Drug Product Category, Application and Specification
            9.1.2.1 Product A
            9.1.2.2 Product B
        9.1.3 MedImmune LLC Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.1.4 Main Business/Business Overview
    9.2 Neovacs SA
        9.2.1 Company Basic Information, Manufacturing Base and Competitors
        9.2.2 Dermatomyositis Drug Product Category, Application and Specification
            9.2.2.1 Product A
            9.2.2.2 Product B
        9.2.3 Neovacs SA Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.2.4 Main Business/Business Overview
    9.3 Novartis AG
        9.3.1 Company Basic Information, Manufacturing Base and Competitors
        9.3.2 Dermatomyositis Drug Product Category, Application and Specification
            9.3.2.1 Product A
            9.3.2.2 Product B
        9.3.3 Novartis AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.3.4 Main Business/Business Overview
    9.4 Octapharma AG
        9.4.1 Company Basic Information, Manufacturing Base and Competitors
        9.4.2 Dermatomyositis Drug Product Category, Application and Specification
            9.4.2.1 Product A
            9.4.2.2 Product B
        9.4.3 Octapharma AG Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.4.4 Main Business/Business Overview
    9.5 Pfizer Inc
        9.5.1 Company Basic Information, Manufacturing Base and Competitors
        9.5.2 Dermatomyositis Drug Product Category, Application and Specification
            9.5.2.1 Product A
            9.5.2.2 Product B
        9.5.3 Pfizer Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.5.4 Main Business/Business Overview
    9.6 Eli Lilly and Company
        9.6.1 Company Basic Information, Manufacturing Base and Competitors
        9.6.2 Dermatomyositis Drug Product Category, Application and Specification
            9.6.2.1 Product A
            9.6.2.2 Product B
        9.6.3 Eli Lilly and Company Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.6.4 Main Business/Business Overview
    9.7 F. Hoffmann-La Roche Ltd
        9.7.1 Company Basic Information, Manufacturing Base and Competitors
        9.7.2 Dermatomyositis Drug Product Category, Application and Specification
            9.7.2.1 Product A
            9.7.2.2 Product B
        9.7.3 F. Hoffmann-La Roche Ltd Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.7.4 Main Business/Business Overview
    9.8 Hope Pharmaceuticals Inc
        9.8.1 Company Basic Information, Manufacturing Base and Competitors
        9.8.2 Dermatomyositis Drug Product Category, Application and Specification
            9.8.2.1 Product A
            9.8.2.2 Product B
        9.8.3 Hope Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.8.4 Main Business/Business Overview
    9.9 Idera Pharmaceuticals Inc
        9.9.1 Company Basic Information, Manufacturing Base and Competitors
        9.9.2 Dermatomyositis Drug Product Category, Application and Specification
            9.9.2.1 Product A
            9.9.2.2 Product B
        9.9.3 Idera Pharmaceuticals Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.9.4 Main Business/Business Overview
    9.10 KPI Therapeutics Inc
        9.10.1 Company Basic Information, Manufacturing Base and Competitors
        9.10.2 Dermatomyositis Drug Product Category, Application and Specification
            9.10.2.1 Product A
            9.10.2.2 Product B
        9.10.3 KPI Therapeutics Inc Dermatomyositis Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        9.10.4 Main Business/Business Overview
    9.11 Marathon Pharmaceuticals LLC

10 Dermatomyositis Drug Maufacturing Cost Analysis
    10.1 Dermatomyositis Drug Key Raw Materials Analysis
        10.1.1 Key Raw Materials
        10.1.2 Price Trend of Key Raw Materials
        10.1.3 Key Suppliers of Raw Materials
        10.1.4 Market Concentration Rate of Raw Materials
    10.2 Proportion of Manufacturing Cost Structure
        10.2.1 Raw Materials
        10.2.2 Labor Cost
        10.2.3 Manufacturing Process Analysis of Dermatomyositis Drug
    10.3 Manufacturing Process Analysis of Dermatomyositis Drug

11 Industrial Chain, Sourcing Strategy and Downstream Buyers
    11.1 Dermatomyositis Drug Industrial Chain Analysis
    11.2 Upstream Raw Materials Sourcing
    11.3 Raw Materials Sources of Dermatomyositis Drug Major Manufacturers in 2016
    11.4 Downstream Buyers

12 Marketing Strategy Analysis, Distributors/Traders
    12.1 Marketing Channel
        12.1.1 Direct Marketing
        12.1.2 Indirect Marketing
        12.1.3 Marketing Channel Development Trend
    12.2 Market Positioning
        12.2.1 Pricing Strategy
        12.2.2 Brand Strategy
        12.2.3 Target Client
    12.3 Distributors/Traders List

13 Market Effect Factors Analysis
    13.1 Technology Progress/Risk
        13.1.1 Substitutes Threat
        13.1.2 Technology Progress in Related Industry
    13.2 Consumer Needs/Customer Preference Change
    13.3 Economic/Political Environmental Change

14 Global Dermatomyositis Drug Market Forecast (2017-2022)
    14.1 Global Dermatomyositis Drug Sales Volume, Revenue and Price Forecast (2017-2022)
       14.1.1 Global Dermatomyositis Drug Sales Volume and Growth Rate Forecast (2017-2022)
       14.1.2 Global Dermatomyositis Drug Revenue and Growth Rate Forecast (2017-2022)
       14.1.3 Global Dermatomyositis Drug Price and Trend Forecast (2017-2022)
    14.2 Global Dermatomyositis Drug Sales Volume, Revenue and Growth Rate Forecast by Region (2017-2022)
       14.2.1 Global Dermatomyositis Drug Sales Volume and Growth Rate Forecast by Regions (2017-2022)
       14.2.2 Global Dermatomyositis Drug Revenue and Growth Rate Forecast by Regions (2017-2022)
       14.2.3 United States Dermatomyositis Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.4 China Dermatomyositis Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.5 Europe Dermatomyositis Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.6 Japan Dermatomyositis Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.7 Southeast Asia Dermatomyositis Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
       14.2.8 India Dermatomyositis Drug Sales Volume, Revenue and Growth Rate Forecast (2017-2022)
    14.3 Global Dermatomyositis Drug Sales Volume, Revenue and Price Forecast by Type (2017-2022)
       14.3.1 Global Dermatomyositis Drug Sales Forecast by Type (2017-2022)
       14.3.2 Global Dermatomyositis Drug Revenue Forecast by Type (2017-2022)
       14.3.3 Global Dermatomyositis Drug Price Forecast by Type (2017-2022)
    14.4 Global Dermatomyositis Drug Sales Volume Forecast by Application (2017-2022)

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology/Research Approach
        16.1.1 Research Programs/Design
        16.1.2 Market Size Estimation
        16.1.3 Market Breakdown and Data Triangulation
    16.2 Data Source
        16.2.1 Secondary Sources
        16.2.2 Primary Sources
    16.3 Disclaimer